Comparison between Aurobindo Pharma Buyback 2026 and Wipro Buyback 2026.
Aurobindo Pharma Buyback 2026 is a Tender Offer buyback proposed to list at BSE, NSE while Wipro Buyback 2026 is a Tender Offer proposed to list at BSE, NSE.
| Aurobindo Pharma Ltd | Wipro Ltd. | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Logo | ![]() | ![]() | ||||||||||||||||||
| Type of Buyback | Tender Offer | Tender Offer | ||||||||||||||||||
| Listing At | BSE, NSE | BSE, NSE | ||||||||||||||||||
| Face Value | ₹10 per share | ₹2 per share | ||||||||||||||||||
| Buyback Price | ₹1475 per share | ₹250 per share | ||||||||||||||||||
| Issue Size | 54,23,728 shares | 60,00,00,000 shares | ||||||||||||||||||
| Issue Size (Amount) | ₹800.00 Crores | ₹15,000.00 Crores | ||||||||||||||||||
| Buyback Ratio |
Note:
|
Note:
| ||||||||||||||||||
| Registrar | Kfin Technologies Ltd. | Kfin Technologies Ltd. | ||||||||||||||||||
| Lead Managers | Axis Capital Ltd. | JM Financial Ltd. | ||||||||||||||||||
| Necessity of the buyback | The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
|
Aurobindo Pharma Buyback 2026 and Wipro Buyback 2026 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Aurobindo Pharma Buyback 2026 Buyback record date is Apr 17, 2026. Wipro Buyback 2026 Buyback record date is Jun 05, 2026.
| Aurobindo Pharma Ltd | Wipro Ltd. | |
|---|---|---|
| Record Date | Apr 17, 2026 | Jun 05, 2026 |
| Offer Open Date | Apr 23, 2026 | Jun 11, 2026 |
| Offer Closure Date | Apr 29, 2026 | Jun 17, 2026 |
| Last date for receipt of tender forms | Apr 29, 2026 | Jun 17, 2026 |
| Finalisation of buyback | May 07, 2026 | Jun 23, 2026 |
| Last Date for settlment of bids | May 07, 2026 | Jun 24, 2026 |
| Last Date for extinguishment of shares | May 18, 2026 | Jul 06, 2026 |
Comparison of Aurobindo Pharma Buyback 2026 and Wipro Buyback 2026 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.
| Aurobindo Pharma Ltd | Wipro Ltd. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financial | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)Wipro Ltd.'s revenue increased by 5% and profit after tax (PAT) rose by 11% between the financial year ending with March 31, 2026 and March 31, 2025.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock price at BSE | Stock price at BSE (in preceding 3 months)
| Stock price at BSE (in preceding 3 months)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock price at NSE | Stock price at NSE (in preceding 3 months)
| Stock price at NSE (in preceding 3 months)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||